Loading
A phase 1/2 trial of Glofitamab, Atezolizumab, Obinutuzumab, Tocilizumab and Polatuzumab vedotin in hodgkin lymphoma, run by Hoffmann-La Roche, active and no longer recruiting.
An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma is a phase 1/2 interventional study registered as NCT03533283 by Hoffmann-La Roche, with 211 participants enrolled, started 2018-05-08 and due to reach its primary completion in 2026-10-16. Interventions recorded: Glofitamab, Atezolizumab, Obinutuzumab, Tocilizumab, Polatuzumab Vedotin and 89Zr-Df-IAB22M2C.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Tocilizumab, Glofitamab, Flatiron Health (Roche), Obinutuzumab and the tag pipeline.
Shares Glofitamab, Flatiron Health (Roche), Obinutuzumab, T-cell engagers (bispecific) and the tag pipeline.
Shares Tocilizumab, Glofitamab, Flatiron Health (Roche), T-cell engagers (bispecific) and the tag pipeline.
Shares Flatiron Health (Roche), Atezolizumab, Monoclonal antibodies, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Flatiron Health (Roche), Atezolizumab, Monoclonal antibodies, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Flatiron Health (Roche), Atezolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Flatiron Health (Roche), Atezolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Flatiron Health (Roche), Atezolizumab, Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/